AQR-008
Hypercholesterolemia
Pre-clinicalActive
Key Facts
About Aqur Biosciences
Aqur Biosciences is a private, preclinical-stage biotech company founded in 2019, targeting the vast cardiovascular disease market with a novel oral therapy. The company's lead candidate, AQR-008, is an oral PCSK9-pathway modulator designed to be a more user-friendly and accessible option for managing high cholesterol. Operating from Southern California, Aqur is in the early stages of research and development, positioning itself in a competitive landscape dominated by injectable PCSK9 inhibitors. Its success hinges on demonstrating clinical efficacy and differentiation for its oral approach.
View full company profileTherapeutic Areas
Other Hypercholesterolemia Drugs
| Drug | Company | Phase |
|---|---|---|
| VXX-401 | Vaxxinity | Phase 1 |
| Atorvastatin Oral Liquid Suspension | CMP Pharma | Approved |
| AFFITOPE® AT04 (licensed to Frontier Biotech) | AFFiRiS | Phase 1 |
| Leqvio® (inclisiran) | Novartis | Approved |
| MK-0616 | Merck | Phase 3 |
| SHR-1209 | Jiangsu Hengrui Medicine | Phase III |
| IBI-306 | Innovent Biologics | NDA Submitted |
| Inusiran (AK102) | Akeso | Approved |
| Obicetrapib + Ezetimibe FDC | NewAmsterdam Pharma Company | Phase 3 |